Dopamine receptors in human lymphocytes: Radioligand binding and quantitative RT-PCR assays

Journal of Neuroscience Methods

Volumn 174, Issue 2, 2008, Pages 272-280

  Kirillova, Galina P ^a   Hrutkay, Rebecca J ^a   Shurin, Michael R ^b   Shurin, Galina V ^b   Tourkova, Irina L ^b   Vanyukov, Michael M ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

DRD1; DRD2; DRD3; DRD4; DRD5; Endophenotypes; Gene expression; Intermediate trait

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; RADIOLIGAND; SEROTONIN RECEPTOR;

ARTICLE; BINDING ASSAY; BINDING SITE; BLOOD VOLUME; BRAIN; CELL MEMBRANE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL MEMBRANE; DOPAMINE ANTAGONISTS; HUMANS; LYMPHOCYTES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 50949097912     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2008.07.018     Document Type: Article

References (65)

1. Amenta F., Bronzetti E., Felici L., Ricci A., and Tayebati S.K. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J Auton Pharmacol 19 (1999) 151-159
2. Aune T.M., McGrath K.M., Sarr T., Bombara M.P., and Kelley K.A. Expression of 5HT1a receptors on activated human T cells. Regulation of cyclic AMP levels and T cell proliferation by 5-hydroxytryptamine. J Immunol 151 (1993) 1175-1183
3. Barbanti P., Fabbrini G., Ricci A., Bruno G., Cerbo R., Bronzetti E., et al. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech Ageing Dev 120 (2000) 65-75
4. Barbanti P., Fabbrini G., Ricci A., Cerbo R., Bronzetti E., Caronti B., et al. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord 14 (1999) 764-771
5. Barbanti P., Fabbrini G., Ricci A., Pascali M.P., Bronzetti E., Amenta F., et al. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia 20 (2000) 15-19
6. Biermann T., Bonsch D., Reulbach U., Kornhuber J., and Bleich S. Dopamine and N-methyl-d-aspartate receptor expression in peripheral blood of patients undergoing alcohol withdrawal. J Neural Transm 114 (2007) 1081-1084
7. Bondy B., and Ackenheil M. 3H-spiperone binding sites in lymphocytes as possible vulnerability marker in schizophrenia. J Psychiatr Res 21 (1987) 521-529
8. Bondy B., Ackenheil M., Elbers R., and Frohler M. Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?. Psychiatry Res 15 (1985) 41-48
9. Bondy B., Ackenheil M., and Engel R.R. Methodology of 3H-spiperone binding to lymphocytes. J Psychiatr Res 24 (1990) 83-92
10. Bondy B., de Jonge S., Pander S., Primbs J., and Ackenheil M. Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. J Neuroimmunol 71 (1996) 139-144
11. Boneberg E.M., von Seydlitz E., Propster K., Watzl H., Rockstroh B., and Illges H. D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+ -T cells. J Neuroimmunol 173 (2006) 180-187
12. Bourne J.A. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev 7 (2001) 399-414
13. Chiu S., Ferris J.A., Johnson R., and Mishra R.K. CNS putative l-prolyl-l-leucyl-glycinamide (PLG) receptors, brain and lymphocyte dopamine receptors. Prog Neuropsychopharmacol Biol Psychiatry 6 (1982) 365-368
14. De Keyser J., Walraevens H., Convents A., Ebinger G., and Vauquelin G. [3H]SCH 23390 labels a novel 5-hydroxytryptamine binding site in human blood platelet membranes. Eur J Pharmacol 162 (1989) 437-445
15. Fiebich B.L., Akundi R.S., Seidel M., Geyer V., Haus U., Muller W., et al. Expression of 5-HT3A receptors in cells of the immune system. Scand J Rheumatol Suppl (2004) 9-11
16. Fleminger S., Jenner P., and Marsden C.D. Are dopamine receptors present on human lymphocytes?. J Pharm Pharmacol 34 (1982) 658-663
17. Frank M.G., Johnson D.R., Hendricks S.E., and Frank J.L. Monocyte 5-HT1A receptors mediate pindobind suppression of natural killer cell activity: modulation by catalase. Int Immunopharmacol 1 (2001) 247-253
18. Griffiths R.S., Chung-a-on K.O., Griffiths K.D., Payne J.W., and Davies J.I. The sequestration of [3H]spiperone by lymphocytes in schizophrenics and their first-degree relatives: a limited vulnerability marker?. J Psychiatr Res 26 (1992) 77-84
19. Grimaldi B., Sibella-Arguelles C., Bonnin A., Fillion M.P., Massot O., Rousselle J.C., et al. Functional properties of 5-HT-moduline in the immune system: a model for central nervous system investigation. Ann N Y Acad Sci 861 (1998) 249-250
20. Gundlach A.L., Largent B.L., and Snyder S.H. 125I-Spiperone: a novel ligand for D2 dopamine receptors. Life Sci 35 (1984) 1981-1988
21. Halbach M., and Henning U. Abnormal glucocorticoid dependent increase of spiperone binding sites on lymphocytes from schizophrenics in vitro. Pharmacopsychiatry 22 (1989) 169-173
22. Hill P., Lai Y., Hnilo J., Lin C.C., Karla M., Bounds S., et al. Cloning, expression, and comparison of the binding characteristics of the known human dopamine receptors. Adv Neurol 69 (1996) 41-52
23. Hurley M.J., Mash D.C., and Jenner P. Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res 87 (2001) 271-279
24. Hyttel J. SCH 23390-the first selective dopamine D-1 antagonist. Eur J Pharmacol 91 (1983) 153-154
25. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., et al. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc Natl Acad Sci USA 98 (2001) 625-628
26. Koob G.F., and Nestler E.J. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 9 (1997) 482-497
27. Kwak Y.T., Koo M.S., Choi C.H., and Sunwoo I. Change of dopamine receptor mRNA expression in lymphocyte of schizophrenic patients. BMC Med Genet 2 (2001) 3
28. Le Fur G., Meininger V., Phan T., Gerard A., Baulac M., and Uzan A. Decrease in lymphocyte spiroperidol binding sites in Parkinsonism. Life Sci 27 (1980) 1587-1591
29. Le Fur G., Zarifian E., Phan T., Cuche H., Flamier A., Bouchami F., et al. [3H]spiroperidol binding on lymphocytes: changes in two different groups of schizophrenic patients and effect of neuroleptic treatment. Life Sci 32 (1983) 249-255
30. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
31. Maher B.S., Marazita M.L., Ferrell R.E., and Vanyukov MM. Dopamine system genes and attention deficit hyperactivity disorder: A meta-analysis. Psychiat Genet 12 (2002) 207-215
32. Maher B.S., Marazita M.L., Moss H.B., and Vanyukov M.M. Segregation analysis of attention deficit hyperactivity disorder. Am J Med Genet 88 (2002) 71-78
33. Maloteaux J.M., Gossuin A., Waterkeyn C., and Laduron P.M. Trapping of labelled ligands in intact cells: a pitfall in binding studies. Biochem Pharmacol 32 (1983) 2543-2548
34. Maloteaux J.M., Waterkein C., and Laduron P.M. Absence of dopamine and muscarinic receptors on human lymphocytes. Arch Int Pharmacodyn Ther 258 (1982) 174-176
35. Marazziti D., Ori M., Nardini M., Rossi A., Nardi I., and Cassano G.B. mRNA expression of serotonin receptors of type 2C and 5A in human resting lymphocytes. Neuropsychobiology 43 (2001) 123-126
36. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132 (2002) 34-40
37. Millan M.J., Newman-Tancredi A., Quentric Y., and Cussac D. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology (Berl) 156 (2001) 58-62
38. Nagai Y., Ueno S., Saeki Y., Soga F., Hirano M., and Yanagihara T. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 46 (1996) 791-795
39. Nagai Y., Ueno S., Saeki Y., Soga F., and Yanagihara T. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun 194 (1993) 368-374
40. Rao M.L., Deister A., and Roth A. Lymphocytes of healthy subjects and schizophrenic patients possess no high-affinity binding sites for spiroperidol. Pharmacopsychiatry 23 (1990) 176-181
41. Ricci A., and Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol 53 (1994) 1-7
42. Ricci A., Bronzetti E., Felici L., Greco S., and Amenta F. Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J Neuroimmunol 92 (1998) 191-195
43. Ricci A., Bronzetti E., Felici L., Tayebati S.K., and Amenta F. Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci Lett 229 (1997) 130-134
44. Ricci A., Bronzetti E., Mignini F., Tayebati S.K., Zaccheo D., and Amenta F. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96 (1999) 234-240
45. Ricci A., Veglio F., and Amenta F. Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with. J Neuroimmunol 58 (1995) 139-144
46. Rotstein E., Mishra R.K., Singal D.P., and Barone D. Lymphocyte 3H-spiroperidol binding in schizophrenia: preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 7 (1983) 729-732
47. Santambrogio L., Lipartiti M., Bruni A., and Dal Toso R. Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol 45 (1993) 113-119
48. 3H]spiperone depend on tissue concentration: analysis and examples. J Neurochem 43 (1984) 221-235
49. Shaskan E.G., Ballow M., Lederman M., Margoles S.L., and Melchreit R. Spiroperidol binding sites on mouse lymphoid cells. Effects of ascorbic acid and psychotropic drugs. J Neuroimmunol 6 (1984) 59-66
50. Spitzer R.L., Williams J.B., and Gibbon M. Instruction manual for the structured clinical interview for DSM-III-R (1987), Biometrics Research Department, New York State Psychiatric Institute, New York
51. Sweet R.A., Hamilton R.L., Healy M.T., Wisniewski S.R., Henteleff R., Pollock B.G., et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 58 (2001) 466-472
52. Sweet R.A., Henteleff R.A., Meinert K.A., DeMichele M.A., Kirshner M.A., Sorisio D.A., et al. Antipsychotic radioreceptor assay: a modification identifying selective receptor effects. Ther Drug Monit 23 (2001) 421-426
53. Takahashi N., Nagai Y., Ueno S., Saeki Y., and Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett 314 (1992) 23-25
54. Tarter R.E., and Vanyukov M.M. Theoretical and operational framework for research into the etiology of substance use disorder. J Child Adolesc Subst Abuse 10 (2001) 1-12
55. Tarter R., Vanyukov M., Giancola P., Dawes M., Blackson T., Mezzich A., et al. Etiology of early age onset substance use disorder: a maturational perspective. Dev Psychopathol 11 (1999) 657-683
56. Vallone D., Picetti R., and Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 24 (2000) 125-132
57. Vanyukov M.M., Maher B.S., Ferrell R.E., Devlin B., Marazita M.L., Kirillova G.P., et al. Association between the dopamine receptor D5 gene and the liability to substance dependence in males: a replication. J Child Adolesc Subst Abuse 10 (2001) 55-63
58. Vanyukov M.M., Moss H.B., Gioio A.E., Hughes H.B., Kaplan B.B., and Tarter R.E. An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. Behav Genet 28 (1998) 75-82
59. Vanyukov M.M., Moss H.B., Kaplan B.B., Kirillova G.P., and Tarter R.E. Antisociality, substance dependence, and the DRD5 gene: a preliminary study. Am J Med Genet 96 (2000) 654-658
60. Vile J.M., and Strange P.G. High-affinity binding sites for neuroleptic drugs in human peripheral blood lymphocytes and their relation to dopamine receptors. A long-standing controversy. Biochem Pharmacol 49 (1995) 747-753
61. Vile J.M., and Strange P.G. D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes. Biol Psychiatry 40 (1996) 881-885
62. Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend 51 (1998) 13-22
63. Wodarz N., Fritze J., Kornhuber J., and Riederer P. 3H-spiroperidol binding to human peripheral mononuclear cells: methodological aspects. Biol Psychiatry 31 (1992) 291-303
64. Zhou Q.Y., Grandy D.K., Thambi L., Kushner J.A., Van Tol H.H., Cone R., et al. Cloning and expression of human and rat D1 dopamine receptors. Nature 347 (1990) 76-80
65. Zvara A., Szekeres G., Janka Z., Kelemen J.Z., Cimmer C., Santha M., et al. Over-expression of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic peripheral blood lymphocytes as potential diagnostic markers. Dis Markers 21 (2005) 61-69